

Robert L Coleman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2080776/publications.pdf>

Version: 2024-02-01

235
papers

18,725
citations

15495

65
h-index

13365

130
g-index

244
all docs

244
docs citations

244
times ranked

20141
citing authors

#	ARTICLE	IF	CITATIONS
1	Malignant diseases of the ovary, fallopian tube, and peritoneum. , 2022, , 707-753.e7.		2
2	A randomized phase II trial of everolimus and letrozole or hormonal therapy in women with advanced, persistent or recurrent endometrial carcinoma: A GOG Foundation study. <i>Gynecologic Oncology</i> , 2022, 164, 481-491.	0.6	19
3	Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer – an ancillary data analysis of the VELIA trial. <i>Gynecologic Oncology</i> , 2022, 164, 278-287.	0.6	6
4	Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study. <i>Gynecologic Oncology</i> , 2022, 164, 245-253.	0.6	15
5	Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG) Tj ETQq1 1 0.784314 rgBT /Over 541-553.	6.3	75
6	Mitigation and management strategies for ocular events associated with tisotumab vedotin. <i>Gynecologic Oncology</i> , 2022, 165, 385-392.	0.6	20
7	A phase II study of MK-2206, an AKT inhibitor, in uterine serous carcinoma. <i>Gynecologic Oncology Reports</i> , 2022, 40, 100974.	0.3	5
8	Clinical analysis of pathologic complete responders in advanced-stage ovarian cancer. <i>Gynecologic Oncology</i> , 2022, 165, 82-89.	0.6	2
9	Is there a “low-risk” patient population in advanced epithelial ovarian cancer?: a critical analysis. <i>American Journal of Obstetrics and Gynecology</i> , 2022, 227, 728-734.	0.7	3
10	A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA – MONO/GOG-3020/ENGOT-ov45). <i>Journal of Clinical Oncology</i> , 2022, 40, 3952-3964.	0.8	125
11	A phase III study of transdermal granisetron versus oral ondansetron for women with gynecologic cancers receiving pelvic chemoradiation. <i>Supportive Care in Cancer</i> , 2021, 29, 213-222.	1.0	2
12	Prospective phase II trial of levonorgestrel intrauterine device: nonsurgical approach for complex atypical hyperplasia and early-stage endometrial cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2021, 224, 191.e1-191.e15.	0.7	56
13	A multicenter open-label randomized phase II trial of paclitaxel plus EP-100, a novel LHRH receptor-targeted, membrane-disrupting peptide, versus paclitaxel alone for refractory or recurrent ovarian cancer. <i>Gynecologic Oncology</i> , 2021, 160, 418-426.	0.6	7
14	The role of secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer: what do the trials tell us?. <i>Journal of Gynecologic Oncology</i> , 2021, 32, e20.	1.0	2
15	A Modified 2 Tier Chemotherapy Response Score (CRS) and Other Histopathologic Features for Predicting Outcomes of Patients with Advanced Extrauterine High-Grade Serous Carcinoma after Neoadjuvant Chemotherapy. <i>Cancers</i> , 2021, 13, 704.	1.7	3
16	Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysis. <i>Cancer</i> , 2021, 127, 2432-2441.	2.0	14
17	Clinical significance of homologous recombination deficiency score testing in endometrial Cancer. <i>Gynecologic Oncology</i> , 2021, 160, 777-785.	0.6	21
18	Proof of principle study of sequential combination atezolizumab and Vigil in relapsed ovarian cancer. <i>Cancer Gene Therapy</i> , 2021, , .	2.2	12

#	ARTICLE	IF	CITATIONS
19	Dasatinib, paclitaxel, and carboplatin in women with advanced-stage or recurrent endometrial cancer: A pilot clinical and translational study. <i>Gynecologic Oncology</i> , 2021, 161, 104-112.	0.6	4
20	Phase 1b study of GAS6/AXL inhibitor (AVB-500) in recurrent, platinum-resistant ovarian carcinoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 5566-5566.	0.8	0
21	Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study. <i>Lancet Oncology</i> , The, 2021, 22, 609-619.	5.1	186
22	Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2). <i>Nature Communications</i> , 2021, 12, 2487.	5.8	116
23	Patient characteristics, treatment patterns, and clinical outcomes among patients with previously treated recurrent or metastatic cervical cancer: A community oncology-based analysis. <i>Gynecologic Oncology</i> , 2021, 161, 422-428.	0.6	8
24	Cardiac safety of trabectedin monotherapy or in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancer. <i>Cancer Medicine</i> , 2021, 10, 3565-3574.	1.3	6
25	Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 949-958.	1.2	7
26	Incidence of myelodysplastic syndrome and acute myeloid leukemia in patients receiving poly-ADP ribose polymerase inhibitors for the treatment of solid tumors: A meta-analysis of randomized trials. <i>Gynecologic Oncology</i> , 2021, 161, 653-659.	0.6	26
27	Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2. <i>Gynecologic Oncology</i> , 2021, 161, 668-675.	0.6	7
28	The GOG partners: A program for industry sponsored clinical trials in gynecologic oncology within the GOG foundation. <i>Gynecologic Oncology</i> , 2021, 162, 203-209.	0.6	4
29	Progression-free survival by investigator versus blinded independent central review in newly diagnosed patients with high-grade serous ovarian cancer: Analysis of the VELIA/GOG-3005 trial. <i>Gynecologic Oncology</i> , 2021, 162, 375-381.	0.6	7
30	MEK inhibition overcomes resistance to EphA2-targeted therapy in uterine cancer. <i>Gynecologic Oncology</i> , 2021, 163, 181-190.	0.6	5
31	CD63-mediated cloaking of VEGF in small extracellular vesicles contributes to anti-VEGF therapy resistance. <i>Cell Reports</i> , 2021, 36, 109549.	2.9	20
32	ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENAâ€œMONO) and rucaparib in combination with nivolumab (ATHENAâ€œCOMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 1589-1594.	1.2	40
33	Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum-based regimen and disease at baseline on efficacy and safety. <i>Cancer Medicine</i> , 2021, 10, 7162-7173.	1.3	4
34	Phase 1b Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 6354-6365.	3.2	31
35	Rational Combination of CRM1 Inhibitor Selinexor and Olaparib Shows Synergy in Ovarian Cancer Cell Lines and Mouse Models. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 2352-2361.	1.9	5
36	Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer. <i>Gynecologic Oncology</i> , 2021, 163, 490-497.	0.6	20

#	ARTICLE	IF	CITATIONS
37	RaPiDS (GOG-3028): randomized Phase II study of balstilimab alone or in combination with zalifrelimab in cervical cancer. <i>Future Oncology</i> , 2021, 17, 3433-3443.	1.1	21
38	Gemogenovatucl-T (Vigil) maintenance immunotherapy: 3-year survival benefit in homologous recombination proficient (HRP) ovarian cancer. <i>Gynecologic Oncology</i> , 2021, 163, 459-464.	0.6	11
39	Preexisting <i>TP53</i> -Variant Clonal Hematopoiesis and Risk of Secondary Myeloid Neoplasms in Patients With High-grade Ovarian Cancer Treated With Rucaparib. <i>JAMA Oncology</i> , 2021, 7, 1772.	3.4	44
40	Correlation of surgeon radiology assessment with laparoscopic disease site scoring in patients with advanced ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 92-97.	1.2	3
41	Treatment Perspectives for Ovarian Cancer in Europe and the United States: Initial Therapy and Platinum-Sensitive Recurrence after PARP Inhibitors or Bevacizumab Therapy. <i>Current Oncology Reports</i> , 2021, 23, 148.	1.8	7
42	Maintenance Treatment of Newly Diagnosed Advanced Ovarian Cancer: Time for a Paradigm Shift?. <i>Cancers</i> , 2021, 13, 5756.	1.7	11
43	TOP: Time-to-Event Bayesian Optimal Phase II Trial Design for Cancer Immunotherapy. <i>Journal of the National Cancer Institute</i> , 2020, 112, 38-45.	3.0	15
44	Clinical and biological significance of EZH2 expression in endometrial cancer. <i>Cancer Biology and Therapy</i> , 2020, 21, 147-156.	1.5	21
45	Incidence of adverse events in minimally invasive vs open radical hysterectomy in early cervical cancer: results of a randomized controlled trial. <i>American Journal of Obstetrics and Gynecology</i> , 2020, 222, 249.e1-249.e10.	0.7	78
46	Carcinoma of the Ovaries and Fallopian Tubes. , 2020, , 1525-1543.e7.		0
47	Phase II, 2-stage, 2-arm, PIK3CA mutation stratified trial of MK-0752 in recurrent endometrial cancer. <i>International Journal of Cancer</i> , 2020, 147, 413-422.	2.3	31
48	Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 1220-1228.	3.2	77
49	Phase Ib/II study of weekly topotecan and daily gefitinib in patients with platinum resistant ovarian, peritoneal, or fallopian tube cancer. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1768-1774.	1.2	2
50	Gemogenovatucl-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial. <i>Lancet Oncology</i> , The, 2020, 21, 1661-1672.	5.1	69
51	Bevacizumab plus fosbretabulin in recurrent ovarian cancer: Overall survival and exploratory analyses of a randomized phase II NRG oncology/gynecologic oncology group study. <i>Gynecologic Oncology</i> , 2020, 159, 79-87.	0.6	6
52	Phase 2 study of cetuximab (Erbix) in patients with progressive or recurrent endometrial cancer. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1733-1737.	1.2	4
53	The new world of poly-(ADP)-ribose polymerase inhibitors (PARPi) used in the treatment of gynecological cancers. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1608-1618.	1.2	4
54	Enhanced Immunotherapy with LHRH-R Targeted Lytic Peptide in Ovarian Cancer. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 2396-2406.	1.9	7

#	ARTICLE	IF	CITATIONS
55	Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 3494-3505.	0.8	28
56	Movement of Poly-ADP Ribose (PARP) Inhibition into Frontline Treatment of Ovarian Cancer. <i>Drugs</i> , 2020, 80, 1525-1535.	4.9	8
57	Breast cancer (BRCA) gene testing in ovarian cancer. <i>Chinese Clinical Oncology</i> , 2020, 9, 63-63.	0.4	3
58	The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma. <i>Gynecologic Oncology</i> , 2020, 159, 101-111.	0.6	14
59	MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum. <i>Journal of Clinical Oncology</i> , 2020, 38, 3753-3762.	0.8	82
60	Innovation abounds in cancer therapy. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 424-425.	1.2	0
61	Quality of life in patients with cervical cancer after open versus minimally invasive radical hysterectomy (LACC): a secondary outcome of a multicentre, randomised, open-label, phase 3, non-inferiority trial. <i>Lancet Oncology</i> , The, 2020, 21, 851-860.	5.1	57
62	Improving response to progestin treatment of low-grade endometrial cancer. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1811-1823.	1.2	21
63	NRG1/ERBB3 Pathway Activation Induces Acquired Resistance to XPO1 Inhibitors. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 1727-1735.	1.9	5
64	Decision analysis for secondline maintenance treatment of platinum sensitive recurrent ovarian cancer: a review. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 684-694.	1.2	6
65	Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT Tj ETQq1 1 0.7843 14 rgB1/Overlock	1.2	14
66	Everolimus, Letrozole, and Metformin in Women with Advanced or Recurrent Endometrioid Endometrial Cancer: A Multi-Center, Single Arm, Phase II Study. <i>Clinical Cancer Research</i> , 2020, 26, 581-587.	3.2	60
67	Demcizumab combined with paclitaxel for platinum-resistant ovarian, primary peritoneal, and fallopian tube cancer: The SIERRA open-label phase Ib trial. <i>Gynecologic Oncology</i> , 2020, 157, 386-391.	0.6	25
68	A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancer. <i>Gynecologic Oncology</i> , 2020, 156, 535-544.	0.6	30
69	Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 710-722.	5.1	70
70	Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook. <i>Cancer Treatment Reviews</i> , 2020, 86, 102017.	3.4	573
71	Molecular Analysis of Clinically Defined Subsets of High-Grade Serous Ovarian Cancer. <i>Cell Reports</i> , 2020, 31, 107502.	2.9	69
72	PARP inhibition in the ovarian cancer patient: Current approvals and future directions. , 2020, 213, 107588.		7

#	ARTICLE	IF	CITATIONS
73	Discrepancy in calculated and measured glomerular filtration rates in patients treated with PARP inhibitors. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 89-93.	1.2	30
74	Fertility-sparing treatment in early endometrial cancer: current state and future strategies. <i>Obstetrics and Gynecology Science</i> , 2020, 63, 417-431.	0.6	48
75	Joint ENGOT and GOG Foundation requirements for trials with industry partners. <i>Gynecologic Oncology</i> , 2019, 154, 255-258.	0.6	7
76	Poly-ADP-ribose polymerase inhibitor use in ovarian cancer: expanding indications and novel combination strategies. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 956-968.	1.2	4
77	Prospective pilot trial with combination of propranolol with chemotherapy in patients with epithelial ovarian cancer and evaluation on circulating immune cell gene expression. <i>Gynecologic Oncology</i> , 2019, 154, 524-530.	0.6	24
78	OVQUEST â€œ Life after the diagnosis and treatment of ovarian cancer - An international survey of symptoms and concerns in ovarian cancer survivors. <i>Gynecologic Oncology</i> , 2019, 155, 126-134.	0.6	26
79	Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 1929-1939.	13.9	217
80	Safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent endometrial cancer: An NRG Oncology/GOG study. <i>Gynecologic Oncology</i> , 2019, 155, 420-428.	0.6	28
81	Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 2403-2415.	13.9	627
82	Heterotypic CAF-tumor spheroids promote early peritoneal metastasis of ovarian cancer. <i>Journal of Experimental Medicine</i> , 2019, 216, 688-703.	4.2	145
83	Advancing Drug Development in Gynecologic Malignancies. <i>Clinical Cancer Research</i> , 2019, 25, 4874-4880.	3.2	18
84	Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 2317-2328.	0.8	289
85	Adaptive responses in a PARP inhibitor window of opportunity trial illustrate limited functional interlesional heterogeneity and potential combination therapy options. <i>Oncotarget</i> , 2019, 10, 3533-3546.	0.8	19
86	Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference. <i>Cancer</i> , 2019, 125, 1963-1972.	2.0	39
87	Microsatellite instability in endometrial cancer: New purpose for an old test. <i>Cancer</i> , 2019, 125, 2154-2163.	2.0	23
88	A randomized phase II study of letrozole vs. observation in patients with newly diagnosed uterine leiomyosarcoma (uLMS). <i>Gynecologic Oncology Reports</i> , 2019, 27, 1-4.	0.3	10
89	Olaparib and Î±-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial. <i>Lancet Oncology</i> , The, 2019, 20, 570-580.	5.1	191
90	GnRH-Râ€œTargeted Lytic Peptide Sensitizes<i>BRCA</i>Wild-type Ovarian Cancer to PARP Inhibition. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 969-979.	1.9	12

#	ARTICLE	IF	CITATIONS
91	Presumed early ovarian cancer with isolated tumor cells in para-aortic sentinel nodes. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 216-220.	1.2	8
92	Phase III trials in ovarian cancer: The evolving landscape of front line therapy. <i>Gynecologic Oncology</i> , 2019, 153, 436-444.	0.6	17
93	Joint ENGOT and GOG Foundation requirements for trials with industry partners. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 1094-1097.	1.2	6
94	Tumor core biopsies adequately represent immune microenvironment of high-grade serous carcinoma. <i>Scientific Reports</i> , 2019, 9, 17589.	1.6	12
95	Emerging serine-threonine kinase inhibitors for treating ovarian cancer. <i>Expert Opinion on Emerging Drugs</i> , 2019, 24, 239-253.	1.0	6
96	Exploring and comparing adverse events between PARP inhibitors. <i>Lancet Oncology</i> , The, 2019, 20, e15-e28.	5.1	287
97	<i>BRCA</i> Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. <i>Cancer Discovery</i> , 2019, 9, 210-219.	7.7	278
98	Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer. <i>JAMA Oncology</i> , 2019, 5, e183773.	3.4	60
99	Maintenance Treatment for Recurrent Ovarian Carcinoma – Evidence Supporting the Efficacy and Safety of PARP Inhibitors. <i>European Oncology and Haematology</i> , 2019, 15, 29.	0.0	1
100	Clinical trial methodology in rare gynecologic tumor research: Strategies for success. <i>Gynecologic Oncology</i> , 2018, 149, 605-611.	0.6	8
101	Targeted Therapy and Molecular Genetics. , 2018, , 470-492.e10.		3
102	Inhibiting Nuclear Phospho-Progesterone Receptor Enhances Antitumor Activity of Onapristone in Uterine Cancer. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 464-473.	1.9	4
103	Paclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer. <i>JAMA Oncology</i> , 2018, 4, 196.	3.4	60
104	Management and Treatment of Recurrent Epithelial Ovarian Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2018, 32, 965-982.	0.9	40
105	Using PARP Inhibitors in the Treatment of Patients With Ovarian Cancer. <i>Current Treatment Options in Oncology</i> , 2018, 19, 1.	1.3	49
106	Concordance of a laparoscopic scoring algorithm with primary surgery findings in advanced stage ovarian cancer. <i>Gynecologic Oncology</i> , 2018, 151, 428-432.	0.6	19
107	Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer. <i>New England Journal of Medicine</i> , 2018, 379, 1895-1904.	13.9	1,274
108	A practical guide for the safe implementation of early phase drug development and immunotherapy program in gynecologic oncology practice. <i>Gynecologic Oncology</i> , 2018, 151, 374-380.	0.6	1

#	ARTICLE	IF	CITATIONS
109	Response to pembrolizumab in a heavily treated patient with metastatic ovarian carcinosarcoma. <i>Gynecologic Oncology Research and Practice</i> , 2018, 5, 6.	3.6	13
110	Defining Survivorship Trajectories Across Patients With Solid Tumors. <i>JAMA Oncology</i> , 2018, 4, 1519.	3.4	38
111	Metastatic gynecologic malignancies: advances in treatment and management. <i>Clinical and Experimental Metastasis</i> , 2018, 35, 521-533.	1.7	11
112	Rucaparib in ovarian cancer: an update on safety, efficacy and place in therapy. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591877848.	1.4	23
113	Rucaparib in ovarian cancer: extending the use of PARP inhibitors in the recurrent disease. <i>Future Oncology</i> , 2018, 14, 3101-3110.	1.1	10
114	Race and nodal disease status are prognostic factors in patients with stage IVB cervical cancer. <i>Oncotarget</i> , 2018, 9, 32321-32330.	0.8	10
115	Individualized Medicine in Ovarian Cancer: Are We There Yet?. <i>Gynecologic Oncology</i> , 2017, 144, 229-231.	0.6	0
116	Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum. <i>Journal of Clinical Oncology</i> , 2017, 35, 1103-1111.	0.8	186
117	Preclinical Mammalian Safety Studies of EPHARNA (DOPC Nanoliposomal EphA2-Targeted siRNA). <i>Molecular Cancer Therapeutics</i> , 2017, 16, 1114-1123.	1.9	94
118	A multicenter assessment of the ability of preoperative computed tomography scan and CA-125 to predict gross residual disease at primary debulking for advanced epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2017, 145, 27-31.	0.6	95
119	Bevacizumab and paclitaxel+carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 779-791.	5.1	460
120	Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2017, 18, 75-87.	5.1	975
121	Secondary Somatic Mutations Restoring <i>RAD51C</i> and <i>RAD51D</i> Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. <i>Cancer Discovery</i> , 2017, 7, 984-998.	7.7	310
122	FDA ovarian cancer clinical trial endpoints workshop: A Society of Gynecologic Oncology White Paper. <i>Gynecologic Oncology</i> , 2017, 147, 3-10.	0.6	36
123	Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2. <i>Gynecologic Oncology</i> , 2017, 147, 267-275.	0.6	222
124	Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet</i> , The, 2017, 390, 1949-1961.	6.3	1,261
125	Phase II trial of bevacizumab with dose-dense paclitaxel as first-line treatment in patients with advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2017, 147, 41-46.	0.6	17
126	Differential Effects of EGFL6 on Tumor versus Wound Angiogenesis. <i>Cell Reports</i> , 2017, 21, 2785-2795.	2.9	32

#	ARTICLE	IF	CITATIONS
127	Aurora A Functional Single Nucleotide Polymorphism (SNP) Correlates With Clinical Outcome in Patients With Advanced Solid Tumors Treated With Alisertib, an Investigational Aurora A Kinase Inhibitor. <i>EBioMedicine</i> , 2017, 25, 50-57.	2.7	16
128	Macrophage depletion through colony stimulating factor 1 receptor pathway blockade overcomes adaptive resistance to anti-VEGF therapy. <i>Oncotarget</i> , 2017, 8, 96496-96505.	0.8	49
129	Randomized Phase II Trial of Seribantumab in Combination With Paclitaxel in Patients With Advanced Platinum-Resistant or -Refractory Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 4345-4353.	0.8	68
130	Randomized Phase II Evaluation of Bevacizumab Versus Bevacizumab Plus Fosbretabulin in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 2279-2286.	0.8	63
131	Dll4 Inhibition plus Aflibercept Markedly Reduces Ovarian Tumor Growth. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1344-1352.	1.9	41
132	Sequencing of mutational hotspots in cancer-related genes in small cell neuroendocrine cervical cancer. <i>Gynecologic Oncology</i> , 2016, 141, 588-591.	0.6	53
133	Evaluation of rucaparib and companion diagnostics in the PARP inhibitor landscape for recurrent ovarian cancer therapy. <i>Future Oncology</i> , 2016, 12, 1439-1456.	1.1	63
134	Moving beyond the platinum sensitive/resistant paradigm for patients with recurrent ovarian cancer. <i>Gynecologic Oncology</i> , 2016, 141, 405-409.	0.6	29
135	Characteristics of 10-year survivors of high-grade serous ovarian carcinoma. <i>Gynecologic Oncology</i> , 2016, 141, 260-263.	0.6	73
136	Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2016, 34, 3460-3473.	0.8	318
137	Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2. <i>Gynecologic Oncology</i> , 2016, 143, 27-34.	0.6	81
138	A long-term surviving patient with recurrent low-grade serous ovarian carcinoma treated with the MEK1/2 inhibitor, selumetinib. <i>Gynecologic Oncology Research and Practice</i> , 2016, 3, 5.	3.6	13
139	Endpoints in clinical trials: What do patients consider important? A survey of the Ovarian Cancer National Alliance. <i>Gynecologic Oncology</i> , 2016, 140, 193-198.	0.6	37
140	Validation of a second-generation multivariate index assay for malignancy risk of adnexal masses. <i>American Journal of Obstetrics and Gynecology</i> , 2016, 215, 82.e1-82.e11.	0.7	95
141	Precision medicine. <i>Gynecologic Oncology</i> , 2016, 141, 1.	0.6	11
142	Targeting the tumour microenvironment in ovarian cancer. <i>European Journal of Cancer</i> , 2016, 56, 131-143.	1.3	84
143	Equivalency challenge: Evaluation of Lipodox® as the generic equivalent for Doxil® in a human ovarian cancer orthotopic mouse model. <i>Gynecologic Oncology</i> , 2016, 141, 357-363.	0.6	32
144	Insights into strategies for optimizing ovarian cancer care. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 71-72.	12.5	19

#	ARTICLE	IF	CITATIONS
145	<i>Is it equivalent?</i> Evaluation of the clinical activity of single agent Lipodox® compared to single agent Doxil® in ovarian cancer treatment. <i>Journal of Oncology Pharmacy Practice</i> , 2016, 22, 599-604.	0.5	31
146	Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience. <i>Oncotarget</i> , 2016, 7, 35132-35143.	0.8	9
147	Clinical impact of selective and nonselective beta-blockers on survival in patients with ovarian cancer. <i>Cancer</i> , 2015, 121, 3444-3451.	2.0	157
148	Reply to G. Bogani et al. <i>Journal of Clinical Oncology</i> , 2015, 33, 3516-3516.	0.8	0
149	Patient-reported outcomes as end points and outcome indicators in solid tumours. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 358-370.	12.5	55
150	A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation – An NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2015, 137, 386-391.	0.6	224
151	In Assessing Surrogate Clinical Trial End Points: Drug Safety Is a Requisite. <i>Journal of Clinical Oncology</i> , 2015, 33, 1511-1512.	0.8	1
152	Preclinical and clinical development of siRNA-based therapeutics. <i>Advanced Drug Delivery Reviews</i> , 2015, 87, 108-119.	6.6	382
153	A framework for a personalized surgical approach to ovarian cancer. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 239-245.	12.5	118
154	Evaluation of in vitro chemoresponse profiles in women with Type I and Type II epithelial ovarian cancers: An observational study ancillary analysis. <i>Gynecologic Oncology</i> , 2015, 138, 267-271.	0.6	11
155	A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2015, 138, 30-35.	0.6	57
156	Phase II Study of Everolimus and Letrozole in Patients With Recurrent Endometrial Carcinoma. <i>Journal of Clinical Oncology</i> , 2015, 33, 930-936.	0.8	247
157	PTEN loss is a context-dependent outcome determinant in obese and non-obese endometrioid endometrial cancer patients. <i>Molecular Oncology</i> , 2015, 9, 1694-1703.	2.1	47
158	Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches. <i>Cancer and Metastasis Reviews</i> , 2015, 34, 19-40.	2.7	76
159	XPO1/CRM1 Inhibition Causes Antitumor Effects by Mitochondrial Accumulation of eIF5A. <i>Clinical Cancer Research</i> , 2015, 21, 3286-3297.	3.2	37
160	New ways to successfully target tumor vasculature in ovarian cancer. <i>Current Opinion in Obstetrics and Gynecology</i> , 2015, 27, 58-65.	0.9	11
161	<i>PTEN</i> Expression as a Predictor of Response to Focal Adhesion Kinase Inhibition in Uterine Cancer. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 1466-1475.	1.9	20
162	Predictors of optimal cytoreduction in patients with newly diagnosed advanced-stage epithelial ovarian cancer: Time to incorporate laparoscopic assessment into the standard of care. <i>Gynecologic Oncology</i> , 2015, 137, 553-558.	0.6	69

#	ARTICLE	IF	CITATIONS
163	Erythropoietin Stimulates Tumor Growth via EphB4. <i>Cancer Cell</i> , 2015, 28, 610-622.	7.7	94
164	Successful use of next generation genomic sequencing (NGS)-directed therapy of clear cell carcinoma of the ovary (CCCO) with trametinib and metformin in a patient with chemotherapy-refractory disease. <i>Gynecologic Oncology Research and Practice</i> , 2015, 2, 4.	3.6	13
165	Update on sentinel lymph node biopsy for early-stage vulvar cancer. <i>Gynecologic Oncology</i> , 2015, 138, 472-477.	0.6	34
166	State of the science: Emerging therapeutic strategies for targeting angiogenesis in ovarian cancer. <i>Gynecologic Oncology</i> , 2015, 138, 223-226.	0.6	33
167	Dual Metronomic Chemotherapy with Nab-Paclitaxel and Topotecan Has Potent Antiangiogenic Activity in Ovarian Cancer. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 2677-2686.	1.9	9
168	Immunotherapy Targeting Folate Receptor Induces Cell Death Associated with Autophagy in Ovarian Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 448-459.	3.2	48
169	Molecular Pathways: Translational and Therapeutic Implications of the Notch Signaling Pathway in Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 955-961.	3.2	140
170	Impact of trebananib plus weekly paclitaxel on overall survival (OS) in patients (pts) with recurrent ovarian cancer and ascites: Results from the phase III TRINOVA-1 study.. <i>Journal of Clinical Oncology</i> , 2015, 33, 5503-5503.	0.8	8
171	Focal adhesion kinase. <i>Cancer Biology and Therapy</i> , 2014, 15, 919-929.	1.5	42
172	SGO guidance document for clinical trial designs in ovarian cancer: A changing paradigm. <i>Gynecologic Oncology</i> , 2014, 135, 3-7.	0.6	17
173	Molecular Biomarkers of Residual Disease after Surgical Debulking of High-Grade Serous Ovarian Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 3280-3288.	3.2	80
174	Gynecologic Oncology Research and Practice: a new journal to meet the needs of a growing field. <i>Gynecologic Oncology Research and Practice</i> , 2014, 1, 1.	3.6	1
175	The Search Continues: Looking for Predictive Biomarkers for Response to Mammalian Target of Rapamycin Inhibition in Endometrial Cancer. <i>International Journal of Gynecological Cancer</i> , 2014, 24, 713-717.	1.2	23
176	Biologic Effects of Platelet-Derived Growth Factor Receptor α Blockade in Uterine Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 2740-2750.	3.2	14
177	Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper. <i>Gynecologic Oncology</i> , 2014, 132, 8-17.	0.6	65
178	Notch3 Pathway Alterations in Ovarian Cancer. <i>Cancer Research</i> , 2014, 74, 3282-3293.	0.4	59
179	Hematogenous Metastasis of Ovarian Cancer: Rethinking Mode of Spread. <i>Cancer Cell</i> , 2014, 26, 77-91.	7.7	252
180	Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 799-808.	5.1	279

#	ARTICLE	IF	CITATIONS
181	Utility of 18F-FDG PET/CT in follow-up of patients with low-grade serous carcinoma of the ovary. <i>Gynecologic Oncology</i> , 2014, 133, 100-104.	0.6	22
182	Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904. <i>European Journal of Cancer</i> , 2014, 50, 1638-1648.	1.3	29
183	Antagonism of Tumoral Prolactin Receptor Promotes Autophagy-Related Cell Death. <i>Cell Reports</i> , 2014, 7, 488-500.	2.9	43
184	Platelet-derived growth factor receptor alpha (PDGFR α) targeting and relevant biomarkers in ovarian carcinoma. <i>Gynecologic Oncology</i> , 2014, 132, 166-175.	0.6	31
185	Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase I clinical experience. <i>Oncotarget</i> , 2014, 5, 11168-11179.	0.8	53
186	Investigational agents in development for the treatment of ovarian cancer. <i>Investigational New Drugs</i> , 2013, 31, 213-229.	1.2	25
187	Is bilateral lymphadenectomy for midline squamous carcinoma of the vulva always necessary? An analysis from Gynecologic Oncology Group (GOG) 173. <i>Gynecologic Oncology</i> , 2013, 128, 155-159.	0.6	82
188	Extensive cutaneous metastases of ovarian cancer after prolonged response to liposomal doxorubicin. <i>Gynecologic Oncology Case Reports</i> , 2013, 5, 64-66.	0.9	5
189	Latest research and treatment of advanced-stage epithelial ovarian cancer. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 211-224.	12.5	437
190	Contemporary use of bevacizumab in ovarian cancer. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 283-294.	1.4	14
191	Unmet Needs in Ovarian Cancer: Dividing Histologic Subtypes to Exploit Novel Targets and Pathways. <i>Current Cancer Drug Targets</i> , 2013, 13, 698-707.	0.8	15
192	Phase II, two-stage, two-arm, PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancer (EC).. <i>Journal of Clinical Oncology</i> , 2013, 31, 5524-5524.	0.8	22
193	PTEN loss as a context-dependent determinant of patient outcomes in obese and non-obese endometrioid endometrial cancer patients.. <i>Journal of Clinical Oncology</i> , 2013, 31, 5521-5521.	0.8	1
194	Targeted Therapy and Molecular Genetics. , 2012, , 539-560.e6.		1
195	Lymphatic Mapping and Sentinel Lymph Node Biopsy in Women With Squamous Cell Carcinoma of the Vulva: A Gynecologic Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2012, 30, 3786-3791.	0.8	317
196	Resistance and Escape From Antiangiogenesis Therapy: Clinical Implications and Future Strategies. <i>Journal of Clinical Oncology</i> , 2012, 30, 4026-4034.	0.8	201
197	A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: A Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2012, 127, 538-543.	0.6	82
198	Targeting Angiogenesis in Gynecologic Cancers. <i>Hematology/Oncology Clinics of North America</i> , 2012, 26, 543-563.	0.9	15

#	ARTICLE	IF	CITATIONS
199	Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant low-grade serous carcinoma of the ovary, peritoneum, or fallopian tube. <i>Gynecologic Oncology</i> , 2012, 125, 640-645.	0.6	28
200	Phase I/II study of weekly paclitaxel with or without MLN8237 (alisertib), an investigational aurora kinase inhibitor, in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer (OC), or breast cancer (BrC): Phase I results. <i>Journal of Clinical Oncology</i> , 2012, 30, 5021-5021.	0.8	6
201	ACRIN 6695 perfusion CT as prognostic imaging biomarker in ovarian cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, TPS5114-TPS5114.	0.8	0
202	PRO: Dose-dense Paclitaxel in Combination with Carboplatin is an Acceptable Standard in the Front-Line Management of Advanced Stage Ovarian Cancer. <i>Clinical Ovarian Cancer & Other Gynecologic Malignancies</i> , 2011, 4, 1-3.	0.2	0
203	Management Strategies for Recurrent Platinum-Resistant Ovarian Cancer. <i>Drugs</i> , 2011, 71, 1397-1412.	4.9	132
204	Phase I study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer. <i>Lancet Oncology</i> , The, 2011, 12, 1109-1117.	5.1	91
205	A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: A Gynecologic Oncology Group Study. <i>Gynecologic Oncology</i> , 2011, 122, 111-115.	0.6	101
206	Biological Roles of the Delta Family Notch Ligand Dll4 in Tumor and Endothelial Cells in Ovarian Cancer. <i>Cancer Research</i> , 2011, 71, 6030-6039.	0.4	92
207	Farletuzumab in epithelial ovarian carcinoma. <i>Expert Opinion on Biological Therapy</i> , 2010, 10, 431-437.	1.4	66
208	Combination of gemcitabine and cisplatin is highly active in women with endometrial carcinoma. <i>Cancer</i> , 2010, 116, 4973-4979.	2.0	23
209	A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma. <i>Cancer</i> , 2010, 116, 5415-5419.	2.0	222
210	Erythropoiesis-Stimulating Agents (ESAs) in cervix cancer: The "Black Box" paradox. <i>Cancer Biology and Therapy</i> , 2009, 8, 18-20.	1.5	5
211	Aflibercept in epithelial ovarian carcinoma. <i>Future Oncology</i> , 2009, 5, 591-600.	1.1	27
212	Functional significance of VEGFR2 on ovarian cancer cells. <i>International Journal of Cancer</i> , 2009, 124, 1045-1053.	2.3	124
213	Emergence of truly "individualized" therapy: The poly (adenosine diphosphate-ribose) polymerase inhibitors. <i>Current Oncology Reports</i> , 2009, 11, 414-416.	1.8	0
214	Ovarian cancer. <i>Lancet</i> , The, 2009, 374, 1371-1382.	6.3	594
215	Changing the Paradigm in the Treatment of Platinum-Sensitive Recurrent Ovarian Cancer: From Platinum Doublets to Nonplatinum Doublets and Adding Antiangiogenesis Compounds. <i>International Journal of Gynecological Cancer</i> , 2009, 19, S63-S67.	1.2	65
216	Lymphatic mapping for vulvar cancer: Ready for "Prime-Time"? <i>Current Oncology Reports</i> , 2008, 10, 493-496.	1.8	0

#	ARTICLE	IF	CITATIONS
217	Rationale for combination use of targeted agents in ovarian cancer. <i>Cancer</i> , 2008, 113, 665-667.	2.0	2
218	Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum. <i>Gynecologic Oncology</i> , 2008, 108, 510-514.	0.6	203
219	The Gynecologic Oncology Group's role in the treatment of recurrent cervix cancer: Current clinical trials. <i>Gynecologic Oncology</i> , 2008, 110, S77-S80.	0.6	4
220	Early Changes in CA125 After Treatment with Pegylated Liposomal Doxorubicin or Topotecan Do Not Always Reflect Best Response in Recurrent Ovarian Cancer Patients. <i>Oncologist</i> , 2007, 12, 72-78.	1.9	31
221	Clinical and Biological Significance of Vascular Endothelial Growth Factor in Endometrial Cancer. <i>Clinical Cancer Research</i> , 2007, 13, 7487-7495.	3.2	169
222	Metronomic Chemotherapy Enhances the Efficacy of Antivascular Therapy in Ovarian Cancer. <i>Cancer Research</i> , 2007, 67, 281-288.	0.4	138
223	Current Perspectives on Lymphatic Mapping in Carcinomas of the Uterine Corpus and Cervix. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2006, 4, 471-478.	2.3	5
224	Historical progress in the initial management of ovarian cancer: Intraperitoneal chemotherapy. <i>Current Oncology Reports</i> , 2006, 8, 455-464.	1.8	1
225	Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers. <i>Gynecologic Oncology</i> , 2006, 101, 126-131.	0.6	98
226	CA-125 response in patients with recurrent ovarian or primary peritoneal cancer treated with pegylated liposomal doxorubicin or topotecan. <i>Gynecologic Oncology</i> , 2006, 103, 212-218.	0.6	19
227	Clinical Behavior of Stage II-IV Low-Grade Serous Carcinoma of the Ovary. <i>Obstetrics and Gynecology</i> , 2006, 108, 361-368.	1.2	242
228	Depression, correlates of depression, and receipt of depression care among low-income women with breast or gynecologic cancer. <i>Women's Oncology Review</i> , 2005, 5, 227-228.	0.0	1
229	Lymphatic Mapping and Sentinel Node Identification in Patients With Cervix Cancer Undergoing Radical Hysterectomy and Pelvic Lymphadenectomy. <i>Journal of Clinical Oncology</i> , 2002, 20, 688-693.	0.8	232
230	Effects of a laboratory-based skills curriculum on laparoscopic proficiency: A randomized trial. <i>American Journal of Obstetrics and Gynecology</i> , 2002, 186, 836-842.	0.7	87
231	Intraoperative Lymphatic Mapping and Sentinel Node Identification with Blue Dye in Patients with Vulvar Cancer. <i>Gynecologic Oncology</i> , 2001, 83, 276-281.	0.6	196
232	Intraoperative Lymphatic Mapping in Cervix Cancer Patients Undergoing Radical Hysterectomy: A Pilot Study. <i>Gynecologic Oncology</i> , 2000, 79, 238-243.	0.6	146
233	Vulvar carcinoma. <i>Current Treatment Options in Oncology</i> , 2000, 1, 177-190.	1.3	13
234	Unexplained decrease in measured oxygen saturation by pulse oximetry following injection of Lymphazurin 1% (isosulfan blue) during a lymphatic mapping procedure. , 1999, 70, 126-129.		53

#	ARTICLE	IF	CITATIONS
235	Surgical Therapy of T1 and T2 Vulvar Carcinoma: Further Experience with Radical Wide Excision and Selective Inguinal Lymphadenectomy. <i>Gynecologic Oncology</i> , 1995, 57, 215-220.	0.6	148